scholarly journals Noninvasive Imaging and Radiovirotherapy of Prostate Cancer Using an Oncolytic Measles Virus Expressing the Sodium Iodide Symporter

2009 ◽  
Vol 17 (12) ◽  
pp. 2041-2048 ◽  
Author(s):  
Pavlos Msaouel ◽  
Ianko D Iankov ◽  
Cory Allen ◽  
Ileana Aderca ◽  
Mark J Federspiel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Measles Virus ◽  
Sodium Iodide ◽  
Noninvasive Imaging ◽  
Sodium Iodide Symporter

scholarly journals Effective Radiovirotherapy for Malignant Gliomas by Using Oncolytic Measles Virus Strains Encoding the Sodium Iodide Symporter (MV-NIS)

2012 ◽  
Vol 23 (4) ◽  
pp. 419-427 ◽  
Author(s):  
Mateusz Opyrchal ◽  
Cory Allen ◽  
Ianko Iankov ◽  
Ileana Aderca ◽  
Mark Schroeder ◽  
...  
Keyword(s):  
Measles Virus ◽  
Sodium Iodide ◽  
Malignant Gliomas ◽  
Sodium Iodide Symporter ◽  
Virus Strains

scholarly journals Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer

2014 ◽  
Vol 75 (1) ◽  
pp. 22-30 ◽  
Author(s):  
Evanthia Galanis ◽  
Pamela J. Atherton ◽  
Matthew J. Maurer ◽  
Keith L. Knutson ◽  
Sean C. Dowdy ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Measles Virus ◽  
Sodium Iodide ◽  
Drug Resistant ◽  
Sodium Iodide Symporter

scholarly journals Application of 188Rhenium as an Alternative Radionuclide for Treatment of Prostate Cancer after Tumor-Specific Sodium Iodide Symporter Gene Expression

2007 ◽  
Vol 92 (11) ◽  
pp. 4451-4458 ◽  
Author(s):  
Michael J. Willhauck ◽  
Bibi-Rana Sharif Samani ◽  
Franz-Josef Gildehaus ◽  
Ingo Wolf ◽  
Reingard Senekowitsch-Schmidtke ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Therapeutic Effect ◽  
Half Life ◽  
Sodium Iodide ◽  
Specific Antigen ◽  
Volume Reduction ◽  
Sodium Iodide Symporter ◽  
Nis Gene

Abstract Context: We reported recently the induction of iodide accumulation in prostate cancer cells (LNCaP) by prostate-specific antigen promoter-directed sodium iodide symporter (NIS) expression that allowed a significant therapeutic effect of 131iodine (131I). These data demonstrated the potential of the NIS gene as a novel therapeutic gene, although in some extrathyroidal tumors, therapeutic efficacy may be limited by rapid iodide efflux due to a lack of iodide organification. Objective: In the current study, we therefore studied the potential of 188rhenium (188Re), as an alternative radionuclide, also transported by NIS, with a shorter half-life and higher energy β-particles than 131I. Results: NIS-transfected LNCaP cells (NP-1) concentrated 8% of the total applied activity of 188Re as compared with 16% of 125I, which was sufficient for a therapeutic effect in an in vitro clonogenic assay. γ-Camera imaging of NP-1 cell xenografts in nude mice revealed accumulation of 8–16% injected dose (ID)/g 188Re (biological half-life 12.9 h), which resulted in a 4.7-fold increased tumor absorbed dose (450 mGy/MBq) for 188Re as compared with 131I. After application of 55.5 MBq 131I or 188Re, smaller tumors showed a similar average volume reduction of 86%, whereas in larger tumors volume reduction was significantly increased from 73% after 131I treatment to 85% after application of 188Re. Conclusion: Although in smaller prostate cancer xenografts both radionuclides seemed to be equally effective after prostate-specific antigen promoter-mediated NIS gene delivery, a superior therapeutic effect has been demonstrated for 188Re in larger tumors.

Sign in / Sign up

Export Citation Format

Share Document